Anchor Capital Advisors’s Teva Pharmaceutical Industries Limited TEVA Stock Holding History

Anchor Capital Advisors’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-8,700	Closed	-$400K	–	297
2016 Q3	$400K	Sell	8,700 -11,610	-57%	-$606K	0.01%	225
2016 Q2	$1.02M	Sell	20,310 -14,753	-42%	-$785K	0.03%	167
2016 Q1	$1.88M	Sell	35,063 -4,852	-12%	-$285K	0.05%	138
2015 Q4	$2.62M	Sell	39,915 -846	-2%	-$52.3K	0.07%	137
2015 Q3	$2.3M	Hold	40,761	–	–	0.06%	136
2015 Q2	$2.41M	Sell	40,761 -762	-2%	-$47K	0.05%	141
2015 Q1	$2.59M	Buy	41,523 +2,290	+6%	+$133K	0.06%	143
2014 Q4	$2.26M	Buy	39,233 +14,774	+60%	+$823K	0.05%	153
2014 Q3	$1.31M	Sell	24,459 -7,981	-25%	-$423K	0.03%	181
2014 Q2	$1.7M	Buy	32,440 +15,358	+90%	+$785K	0.03%	164
2014 Q1	$903K	Sell	17,082 -642	-4%	-$29.7K	0.02%	201
2013 Q4	$710K	Sell	17,724 -3,006	-15%	-$118K	0.01%	219
2013 Q3	$783K	Buy	20,730 +6	+0%	+$234	0.02%	193
2013 Q2	$812K	Buy	+20,724	New	+$807K	0.02%	190

Other funds holding TEVA

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $33B AUM 40.62% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

HCM

Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return

Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Nordea Investment Management Stockholm, Sweden $123B AUM 38.85% 1-Year Est. Return

Anchor Capital Advisors's TEVA Position: Q4 2016 in Review

Anchor Capital Advisors sold out of Teva Pharmaceutical Industries Limited (TEVA) in Q4 2016, closing a stake of 8,700 shares — an estimated $400K sold.

Anchor Capital Advisors first reported a position in TEVA in Q2 2013 and held it in 14 quarters. The position peaked at $2.62M in Q4 2015. 739 funds tracked by Wall St. Rank hold TEVA as of Q4 2016.

Anchor Capital Advisors reported no remaining Teva Pharmaceutical Industries Limited position as of Q4 2016 after selling out during the quarter.
Anchor Capital Advisors sold 8,700 Teva Pharmaceutical Industries Limited shares in Q4 2016, an estimated $400K.
Anchor Capital Advisors first reported a position in Teva Pharmaceutical Industries Limited in Q2 2013 and held it in 14 quarters.
Anchor Capital Advisors's Teva Pharmaceutical Industries Limited position peaked at $2.62M in Q4 2015.
739 funds tracked by Wall St. Rank held Teva Pharmaceutical Industries Limited as of Q4 2016.

Based on Anchor Capital Advisors's 13F filing for Q4 2016, filed 8 Feb 2017.